Yang Wenjing, Lin Peihong, Gao Rui, Fang Zhengyu, Wang Zhouru, Ma Zhen, Shi Jing, Yu Wenying
School of Pharmacy, Hangzhou Medical College, Hangzhou, 310013, China.
Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, 310013, China.
Mater Today Bio. 2024 Nov 8;29:101332. doi: 10.1016/j.mtbio.2024.101332. eCollection 2024 Dec.
Inflammatory bowel disease (IBD) is a chronic recurrent disease with an increasing incidence year by year. At present, no safe and effective treatment for IBD exists. Thus, there is an urgent need to create new therapeutic options that have decreased adverse effects and positive clinical efficacy. A range of nanomaterials have fueled the advancement of nanomedicine in recent years, which is establishing more appealing and prospective treatment approaches for IBD. However, traditional synthetic nanomaterials still have some problems in the IBD drug delivery process, such as weak targeting ability of vectors, difficulty escaping immune surveillance, and poor biosecurity. Natural sources of biological nanomaterials have been identified to solve the above problems. A drug delivery system based on bionic technology is expected to achieve a new breakthrough in the targeted therapy of IBD by nanotechnology due to its organic integration of low immunogenicity and natural targeting of biological materials and the controllability and versatility of synthetic nanocarrier design. We begin this review by outlining the fundamental traits of both inflammatory and healthy intestinal microenvironments. Subsequently, we review the latest application of a cell-derived bionic drug delivery system in IBD therapy. Finally, we discuss the development prospects of this delivery system and challenges to its clinical translation. Biomimetic nanotherapy is believed to offer a new strategy for the treatment of IBD.
炎症性肠病（IBD）是一种慢性复发性疾病，发病率逐年上升。目前，尚无针对IBD的安全有效的治疗方法。因此，迫切需要开发新的治疗方案，以减少不良反应并具有积极的临床疗效。近年来，一系列纳米材料推动了纳米医学的发展，为IBD建立了更具吸引力和前景的治疗方法。然而，传统的合成纳米材料在IBD药物递送过程中仍存在一些问题，如载体靶向能力弱、难以逃避免疫监视和生物安全性差等。已发现生物纳米材料的天然来源可解决上述问题。基于仿生技术的药物递送系统有望通过纳米技术在IBD的靶向治疗中取得新突破，因为它将生物材料的低免疫原性和天然靶向性与合成纳米载体设计的可控性和多功能性有机结合。我们通过概述炎症性和健康肠道微环境的基本特征来开始本综述。随后，我们回顾了细胞衍生的仿生药物递送系统在IBD治疗中的最新应用。最后，我们讨论了该递送系统的发展前景及其临床转化面临的挑战。仿生纳米疗法被认为为IBD的治疗提供了一种新策略。
